{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:05:27Z","timestamp":1783487127583,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T00:00:00Z","timestamp":1244419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Context\u2002<\/jats:bold> Recombinant human TSH (rhTSH) is used to augment the effect of radioiodine therapy for nontoxic multinodular goitre. Reports of acute thyroid swelling and hyperthyroidism warrant safety studies evaluating whether these side\u2010effects are dose dependent.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To determine the effects on thyroid size and function of various doses of rhTSH.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> In nine healthy male volunteers, the effect of placebo, 0\u00b71, 0\u00b73 and 0\u00b79\u2003mg of rhTSH was examined in a paired design including four consecutive study rounds.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> Main outcome measures were evaluated at baseline, 24\u2003h, 48\u2003h, 96\u2003h, 7\u2003days and 28\u2003days after rhTSH and included: Thyroid volume (TV) estimation by planimetric ultrasound, and thyroid function by serum TSH, free T3, free T4 and Tg levels.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Following placebo or 0\u00b71\u2003mg rhTSH, the TV did not change significantly from baseline at any time. At 24 and 48\u2003h after administration of 0\u00b73\u2003mg rhTSH, the TV increased by 37\u00b74\u2003\u00b1\u200312\u00b73% (SEM) (<jats:italic>P\u2003<\/jats:italic>=\u20030\u00b703) and 45\u00b73\u2003\u00b1\u200316\u00b71% (<jats:italic>P\u2003<\/jats:italic>=\u20030\u00b705) respectively. After 0\u00b79\u2003mg rhTSH, the TV increased by 23\u00b73\u2003\u00b1\u20035\u00b78% (<jats:italic>P\u2003<\/jats:italic>=\u20030\u00b7008) and 35\u00b75\u2003\u00b1\u200318\u00b74% (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702) respectively. The increase in serum FT3, FT4 and thyroglobulin (Tg) was greater when administering 0\u00b73\u2003mg compared with 0\u00b71\u2003mg (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702) and when administering 0\u00b79\u2003mg compared with 0\u00b73\u2003mg (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702). After 0\u00b71\u2003mg rhTSH, the increase in FT3 and Tg was not significantly different from placebo whereas the FT4 increase was significantly higher (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702 compared with placebo).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> In healthy individuals, rhTSH\u2010induced thyroid swelling and hyperthyroidism is rapid and dose dependent. If valid for patients with goitre, our results suggest that these adverse effects are unlikely to be of clinical significance, following doses of rhTSH of 0\u00b71\u2003mg or less.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2009.03650.x","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T11:34:18Z","timestamp":1244460858000},"page":"411-416","source":"Crossref","is-referenced-by-count":30,"title":["Dose\u2010dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0\u00b71, 0\u00b73 and 0\u00b79\u2003mg of rhTSH"],"prefix":"10.1111","volume":"72","author":[{"given":"S\u00f8ren","family":"Fast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viveque E.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen J.","family":"Bonnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021554"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0501"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.14.1476"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01918.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-007-9020-3"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02134.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1210\/jcem.86.4.7405","article-title":"Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects","volume":"86","author":"Torres M.S.","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031783"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2137"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.7.832"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0779"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0300-0664.2001.01425.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.10.3636"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02784.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1986"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(86)90098-0"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-2-260"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1616621"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0485"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0016"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.10.3.253"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.10.3592"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1996.6.457"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02094"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01904.x"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2009.03650.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2009.03650.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:14:38Z","timestamp":1698714878000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2009.03650.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2265.2009.03650.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03650.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,10]]}}}